The role of DPYS, or dihydropyrimidinase, in the hematopoietic system is currently unknown, and it may simply be a marker of methylation defects in CML as is the case in prostate and breast cancer [35]. Here, DPYS is linked to chronic myelogenous leukemia, BCR-ABL1 positive.